查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1190763

酵素联免疫吸附测定 (ELISA) 市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Enzyme-Linked Immunosorbent Assay (Elisa) Market- Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，酵素联免疫吸附测定 (ELISA) 市场预计将以 8% 的复合年增长率增长。

COVID-19 增加了全球对 ELISA 等免疫测定的需求。 这主要是由于感染率增加，这增加了对有效诊断的需求。 根据 2020 年 3 月在 NCBI 期刊上发表的题为“Diagnosing COVID-19”的数据，根据“The Disease and Tools for Detection”，SARS-CoV-2 可以通过 ELISA 进行高精度检测。此外，2021 年 2 月，安捷伦科技公司将推出的“Agilent Dako SARS-CoV -2 IgG 酵素联免疫吸附测定（ELISA）试剂盒”正在发售。 因此，对具有成本效益的诊断以接受适当治疗的需求不断增加，预计将推动市场增长。

HIV、登革热、肝炎、疟疾、流感和其他各种传染病的发病率不断上升是市场增长的主要原因。 根据世卫组织 2022 年 7 月更新的数据，到 2020 年底，全球估计有 3770 万人感染艾滋病毒，其中超过三分之二（2560 万）生活在非洲地区。 同一份文件还指出，登革热是世界十大健康威胁之一。 在过去的 50 年里，全球登革热的发病率增加了 30 倍。 根据世界卫生组织 2022 年 6 月的更新，全世界有超过 3.54 亿人患有乙型或丙型肝炎。 此类感染髮生率的增加增加了对诊断的需求。 越来越多地使用先进的诊断工具，例如用于疾病筛查的酵素联免疫吸附测定，正在推动市场的增长。

此外，面临患上各种传染病和慢性病风险的老龄化人口的增加也在推动市场增长方面发挥着关键作用。 NCBI 于 2021 年 7 月更新的数据显示，与年轻患者相比，潜在的严重感染在老年患者中更为常见。 预计这些因素将显着增加对酵素联免疫吸附测定市场的需求，从而促进市场增长。

此外，主要市场参与者在酵素联免疫吸附测定方面的创新也推动了市场增长。 例如，2021 年 9 月，Bio-Rad 推出了 Bio-PlexPro Human IgA and IgM SARS-CoV-2 panel，可检测针对四种 SARS-CoV-2 抗原的 IgA 和 IgM 抗体。 这种多重免疫检测组合已帮助疫苗开发人员确定从开发到临床阶段再到上市后研究的治疗效果。 同样在 2021 年 12 月，ArcticZymes Technologies 推出了一种新的 ELISA 免疫测定产品，这是一种必不可少的消费者支持产品，用于在基因治疗和病毒疫苗製造的生物製造过程中使用 M-SAN HQ 酵素。 此类产品的推出正在推动市场的增长。

但是，严格的许可规定和操作设备的熟练工人短缺限制了市场的增长。

酵素联免疫吸附测定的市场趋势

疾病诊断应用领域有望占据主要市场份额

由于酵素联免疫吸附试验在诊断肿瘤抗原方面的应用不断扩大，疾病诊断领域有望占据很大份额。 根据 2022 年 2 月发布的世界卫生组织关于癌症的重要事实，全世界每年约有 400,000 名儿童患癌症。 根据 GLOBOCAN 2020 报告，2020 年全球癌症患者总数将达到约 19,292,789 人。 据估计，到 2040 年将增加到 28,887,940 人。 根据2020年5月发表在Nature Scientific报告上的一篇论文，ELISA还可用于检测前列腺癌抗原和乳腺癌抗原。 因此，全世界癌症患者数量的增加增加了对 ELISA 的需求。 它可以作为测量癌症标誌物和抗原的有效工具。

此外，根据世界卫生组织发布的《2021年全球结核病报告》，预计2020年全球约有987万人患有结核病。 2022年7月，WHO公布了《关于HIV的关键事实》，到2021年底，全球约有3840万人感染HIV，仅2021年就有约150万人新登记，我猜。 因此，越来越多的传染病患者将增加对早期检测的需求，预计这将在预测期内进一步推动该领域的增长。

此外，2022 年 9 月，PerkinElmer 的 Oxford Immunotech 宣布美国 FDA 已批准使用 T 细胞选择试剂盒进行 T 点自动化。 具有成本效益的诊断和抗原检测的高精度相结合，增加了对 ELISA 的需求并推动了市场的增长。

预计北美将占据重要的市场份额

目前，北美在酵素联免疫吸附测定 (ELISA) 市场占据主导地位，预计在预测期内将继续如此。 此外，影响该地区的大流行增加了对这些免疫测定的需求。 在北美地区，美国占据了最大的市场份额。

这是由于慢性病、传染病、老年人口的增加，以及医疗基础设施的发展和医疗设备的普及。 在美国，癌症是导致住院的主要原因之一。 根据 GLOBOCAN 2020 报告，2020 年美国癌症患者总数将约占 2,281,658 人。 据估计，到 2040 年将增加到 3,123,452。 根据国家糖尿病统计报告，2020 年美国约有 3730 万人被发现患有糖尿病，约有 9600 万成年人被发现处于糖尿病前期。 美国国家肾臟基金会 2020 年的一份报告估计，美国约有 3600 万成年人患有慢性肾病。 疾病预防控制中心 2020 年的一份报告显示，大约有 1570 万美国人患有慢性下呼吸道疾病。 因此，随着慢性病患病率的增加，对免疫测定的需求不断增加，推动了市场的发展。

此外，政府机构和製药公司对慢性病和糖尿病等疾病的高额研发支出也是推动该地区市场的主要因素之一。 例如，根据美国研究和製药製造商协会的数据，生物製药行业在 2021 年的研发投资估计将达到 1023 亿美元。

因此，上述所有因素预计将在预测期内提振该地区的市场。

酵素联免疫吸附测定市场的竞争分析

酵素联免疫吸附测定 (ELISA) 市场分散且竞争激烈，由几家主要参与者组成。 从市场份额的角度来看，一些主要参与者目前主导着市场。 目前的市场主导者包括 Thermo Fisher Scientific、Abcam PLC、Merck kGaA、Bio-Rad Laboratories, Inc、Cell Biolabs, Inc、Promega Corporation、Zeus Scientific, Inc、Enzo Life Sciences, Inc、Arbor Assays, Inc、Biolegend、Agilent Technologies、公司、J.Mitra&Co.Pvt Ltd 等

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 慢性病和感染的发病率增加
    • 提高人们对早期诊断的认识
  • 市场製约因素
    • 与授权相关的严格规定
    • 缺乏熟练操作设备的人员
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：100 万美元）

  • 通过方法
    • 直接 ELISA
    • 独立酵素联免疫吸附试验
    • 夹心法
    • 竞争性 ELISA 方法
  • 通过申请
    • 疾病诊断
    • 疫苗开发
    • 其他应用
  • 按地区列出
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Thermo Fisher Scientific
    • Abcam Plc
    • Merck KGaA
    • Bio-Rad Laboratories, Inc
    • Cell Biolabs, Inc
    • Promega Corporation
    • Zeus Scientific, Inc
    • Enzo-lifesciences, Inc
    • Arbor Assays, Inc
    • Biolegend, Inc
    • Agilient Technologies, Inc
    • J. Mitra & Co. Pvt Ltd

第7章 市场机会今后动向

简介目录
Product Code: 90441

The enzyme-linked immunosorbent assay (ELISA) market is projected to register a CAGR of 8% during the forecast period.

COVID-19 has increased the demand for immunoassays like ELISA across the globe. This is mainly due to the increase in infection rates, which increased the necessity for effective diagnosis. According to the data published in the NCBI Journal in March 2020 titled "Diagnosing COVID-19: The Disease and Tools for Detection", SARS-CoV-2 can be detected by the ELISA with high accuracy. Moreover, in February 2021, Agilent Technologies Inc. launched the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit to detect immunoglobulin G (IgG) antibodies qualitatively to SARS-CoV-2 in human serum or plasma. Thus, the increasing demand for cost-effective diagnoses to get the appropriate treatment is expected to drive the market's growth.

The increasing incidence of infectious diseases such as HIV, dengue, hepatitis, malaria, influenza, and various other infections is a significant factor contributing to the market's growth. According to the WHO data updated in July 2022, an estimated 37.7 million people were living with HIV globally at the end of 2020, and over two-thirds (25.6 million) of them are in the African region. Also, the same source stated that dengue fever is one of the top ten global health threats. There has been a 30-fold increase in global dengue incidence over the past 50 years. According to World Health Organization updates from June 2022, over 354 million people across the globe live with Hepatitis B or C infections. Such an increasing incidence of infectious diseases increased the demand for diagnosis. The increased usage of advanced diagnostic tools, such as enzyme-linked immunosorbent assays for screening diseases, is attributed to the market's growth.

Furthermore, the increase in the geriatric population at risk of developing various infections and chronic disorders also plays a crucial role in driving the market's growth. as per the data updated by NCBI in July 2021, potentially serious infections are quite common in older patients than in younger ones. Such factors are expected to significantly increase the demand for the enzyme-linked immunosorbent assay market, thereby increasing the market's growth.

Moreover, key market players' innovations in enzyme immunoassays also add to the market growth. For instance, in September 2021, Bio-Rad launched the Bio-PlexPro Human IgA and IgM SARS-CoV-2 panels to detect IgA and IgM antibodies against four SARS-CoV-2 antigens. The multiplex immunoassay panels helped the vaccine developers determine therapeutic efficacy from development through clinical phases and postmarket surveillance studies. Also, in December 2021, ArcticZymes Technologies launched a new ELISA immunoassay product, an essential support product for consumers which used the M-SAN HQ enzyme in biomanufacturing processes for gene therapy and viral vaccine production. Such product launches are boosting market growth.

However, stringent regulations for approval and a lack of skilled personnel handling equipment are restraining the market's growth.

Enzyme-Linked Immunosorbent Assay Market Trends

Disease Diagnosis Application Segment is Expected to Hold a Major Market Share

The disease diagnosis segment is expected to hold a significant share due to the increasing application of enzyme-linked immunosorbent assay tests in diagnosing tumor antigens. According to the World Health Organization's key facts on cancer published in February 2022, around 400,000 children worldwide develop cancer every year. According to the GLOBOCAN 2020 report, the total number of people in the world affected by cancer in 2020 accounts for around 19,292,789 cases. The number is estimated to rise to 28,887,940 cases by 2040. According to the article published in Nature Scientific report in May 2020, ELISA can also be used to detect prostate cancer antigens and breast cancer antigens. This increase in cancer cases across the globe increased the demand for ELISA. It can serve as an effective tool for measuring cancer markers or antigens.

Also, according to the Global Tuberculosis Report 2021 published by the WHO, around 9.87 million people worldwide were estimated to be affected by tuberculosis in 2020. Also, the WHO, in its July 2022 key facts on HIV, estimated that around 38.4 million people worldwide would be affected by HIV by the end of the year 2021, with about 1.5 million new cases being registered in 2021 alone. Thus, the increasing cases of infectious diseases are expected to increase the demand for early detection, which is further expected to boost the segment's growth over the forecast period.

Moreover, in September 2022, PerkinElmer's Oxford Immunotec announced that the US FDA had approved using the T-Cell select reagent kit to automate its T-Spot. Cost-effective diagnosis coupled with the accuracy of detection in antigens increased the demand for ELISA and propelled the market's growth.

North America is Expected to Hold a Significant Share in the Market

Currently, North America dominates the market for enzyme-linked immunosorbent assay and is expected to continue its stronghold during the forecast period. The pandemic affecting the region has also increased the need for these immunoassays. United States holds the largest market share in the North American region.

This can be attributed to the increasing incidence rates of chronic disorders, infectious diseases, and the increasing geriatric population, as well as the well-developed healthcare infrastructure and increasing penetration of medical devices in the region. Cancer is one of the leading causes of hospitalization in United States. According to the GLOBOCAN 2020 report, the total number of people in United States affected by cancer in 2020 accounts for around 2,281,658 cases. The number is estimated to rise to 3,123,452 cases by 2040. According to the National Diabetes Statistics Report, in 2020, about 37.3 million people in United States were found to have diabetes; around 96 million adults were found to have pre-diabetes. ​The National Kidney Foundation 2020 estimated that about 36 million adults in United States have chronic kidney diseases. ​A report by the CDC in 2020 showed that around 15.7 million Americans are affected by chronic lower respiratory diseases. Hence, with the increase in the prevalence of chronic diseases, there is an increasing demand for immunoassays, driving the market.

Moreover, high expenditure on R&D by government organizations and pharmaceutical companies for disorders and diseases, such as chronic ailments and diabetes, are some of the primary factors driving the regional market. For instance, as per Pharmaceutical Research and Manufacturers of America, the biopharmaceutical industry invested an estimated USD 102.3 billion in R&D in 2021.

Thus, all factors above are expected to boost the market in the region over the forecast period.

Enzyme-Linked Immunosorbent Assay Market Competitive Analysis

The enzyme-linked immunosorbent assay (ELISA) market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Thermo Fisher Scientific, Abcam PLC, Merck kGaA, Bio-Rad Laboratories, Inc, Cell Biolabs, Inc, Promega Corporation, Zeus Scientific, Inc, Enzo Life Sciences, Inc, Arbor Assays, Inc, Biolegend, Agilient Technologies, Inc, J. Mitra & Co. Pvt Ltd, and others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Chronic and Infectious Diseases
    • 4.2.2 Growing Awareness among People for Early Diagnosis
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulations for Approval
    • 4.3.2 Lack of Skilled Personnel for Handling the Equipment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Method
    • 5.1.1 Direct ELISA
    • 5.1.2 Indirect ELISA
    • 5.1.3 Sandwich ELISA
    • 5.1.4 Competitive ELISA
  • 5.2 By Application
    • 5.2.1 Disease diagnosis
    • 5.2.2 Vaccine Development
    • 5.2.3 Other Applications
  • 5.3 By Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Thermo Fisher Scientific
    • 6.1.2 Abcam Plc
    • 6.1.3 Merck KGaA
    • 6.1.4 Bio-Rad Laboratories, Inc
    • 6.1.5 Cell Biolabs, Inc
    • 6.1.6 Promega Corporation
    • 6.1.7 Zeus Scientific, Inc
    • 6.1.8 Enzo-lifesciences, Inc
    • 6.1.9 Arbor Assays, Inc
    • 6.1.10 Biolegend, Inc
    • 6.1.11 Agilient Technologies, Inc
    • 6.1.12 J. Mitra & Co. Pvt Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS